| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Applied Molecular Evolution, Inc. |
| 3520 Dunhill Street, San Diego, CA 92121 * (858) 597-4990 |
| Business Description | The company is a leader in the emerging field of directed evolution, a process for optimizing genes and proteins for specific commercial purposes. |
| Offering Information Company has | |||
| Trading As | AMEV (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 5/12/00 |
| Domestic Shares Offered | 4,650,000 | Offer Date | 7/26/00 |
| Foreign Shares Offered | 0 | Filing Range | $15.00 - $17.00 |
| Company Shares | 4,650,000 | Offer Price | $19.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.330 |
| Gross Proceeds | $88,350,000 | Selling | $0.800 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 21,200,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CIBC World Markets | Lead Manager | (212) 667-7400 |
| PaineWebber Incorporated | Co-manager | (212) 713-2626 |
| SG Cowen | Co-manager | (212) 495-6000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 | ||
| Revenues | - | - | 3.329 | 2.590 | 2.592 | 0.147 | 0.831 |
| Income from Oper. | - | - | -2.300 | -1.968 | -3.634 | -1.045 | -1.047 |
| Net Income | - | - | -2.221 | -1.867 | -3.215 | -1.014 | -0.815 |
| E.P.S | - | - | - | - | -0.230 | - | -0.060 |
| Revenue Growth (%) | - | - | -22.20 | 0.077 | 465.31 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -3.20 | 0.01 | -1.01 | ||||
| Cash Flow - Inv. | -1.92 | -3.74 | 0.16 | ||||
| Cash Flow - Fin. | -6.28 | 5.11 | 0.00 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 5.50 | Current Assets | 3.56 | Current Ratio | 5.41 |
| Total Liab. | 2.45 | Current Liab. | 0.66 | Debt Ratio | 44.44% |
| Total Equity | 3.06 | Working Cap. | 2.90 | Debt to Equity Ratio | 0.80 |
| Cash | 1.13 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for expansion and enhancement of the AMEsystem technology, internal development projects and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Pillsbury Madison & Sutro |
| Bank's Law Firm | McDermott, Will & Emery |
| Registrar/Transfer Agent | EquiServe |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Domain Partners affiliated entities | 12.60 | |
| Delphi Ventures affiliated entities | 8.40 | |
| Attenuon, LLC | 7.80 | |
| Medicus Venture Partners affiliated entities | 7.20 | |
| HarbourVest Partners III L.P. | 6.10 | |
| MedImmune, Inc. | 5.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||